Titan Medical Inc. (TSE:TMD) (OTCMKTS:TITXF) (FRA:QTN), a robotic surgical technologies company, is currently in the advanced prototype stage with their SPORT Surgical System, which will expand the technology into underserved areas such as general abdominal, gynecologic, urologic and colorectal procedures, in a cost-effective manner. CEO David McNally tells James about the program and the recent move to Columbia University.

TRANSCRIPT:

James West:     David, thanks for joining us today!

David McNally:     I’m delighted to be here, James.

James West:     David, this is about our third interface with Titan Medical, and things are always happening at Titan, which is why I’m always delighted to talk to you guys. And you most recently announced that you’ve actually started with a trial installation of the SPORT Surgical System at Columbia University Medical Center.

David McNally:     Yes, James, and we’re thrilled to be building upon the progress that the team has made since the beginning of this year in 2017, in quickly moving the system to the advanced prototype stage, where it can be deployed and utilized by surgeons in the laboratory. We began earlier this Fall at Florida Hospital’s Nicholson Center with very successful surgeries, and now we’re moving to Columbia as we recently announced.

James West:     Fantastic. And so in terms of getting this system into broad use, where does this sort of put you in that timeline?

David McNally:     We’re excited that our new executive team is on track for achieving all of its published milestones, which means that as we exercise the system in the laboratory at our three centres of excellence, including Florida Hospital, Columbia University, and the IHU in Strasbourg, France, all of which are world-renowned robotic training centres, we will continue to learn about the best procedures for us to explore when we enter the market.

We’re on track for our projection for 2019 as the year that we expect to enter the North American as well as European markets. I can say also that the early surgeon feedback is extremely positive toward our single-incision solution, and even today, procedures are currently being performed while we’re on this podcast that are showing great progress in gynecological procedures performed through a single incision.

James West:     Now as I recall, the company adopted a strategy where instead of hurrying to market several years ago, you elected to delay your market debut, so to speak, in the rationale of being able to service a broader range of procedures. So is the gynecological aspect an example of that?

David McNally:     Yes, it is. And I can say, James, in my 30-year tenure in the medical device industry, I’ve never seen an opportunity of this magnitude. With a multi-billion-dollar robotic surgical market standing right before us, and an opportunity for Titan Medical to have a unique position in that market, I feel like the table is set for a remarkable opportunity.

Gynecologic applications are accompanied by urologic, colorectal, and general surgery applications for our technology, and of course, from an economic perspective, this represents not only a capital equipment revenue opportunity but also service revenue as well as disposables revenue.

James West:     Wow. That’s really interesting. So now, the 900-lb gorilla, the t

VirtualArmour International Inc. (CNSX:VAI) (OTCQB:VTLR) (FRA:3V3) is an enterprise-class IT protection management system. Founder Chris Blisard talks to James about their in-depth services and why their clients weren’t affected by the Wanna Cry and Petya cyber attacks.

TRANSCRIPT:

James West:     Chris, thanks for joining us today.

Chris Blisard:     Thank you for having me.

James West:     Chris, what is it that differentiates VirtualArmour from all the other enterprise-class IT protection management systems out there?

Chris Blisard:     That’s a great question. The landscape is pretty broad when it comes to managed security services, and a lot of what we would consider our competition offers a very vanilla-like solution to their customers. So while they can do some managing and monitoring, they really don’t get in-depth with each of the products that are sitting within that customer’s network.

So when you look at us, there’s a couple of things that really position us differently. First and foremost is our unparalleled response service. Our SLA in our business is 15 minutes. No one else meets that SLA within the managed security services business.

James West:     Sorry, SLA?

Chris Blisard:     Service Level Agreement.

James West:     Okay.

Chris Blisard:     And no one else meets that requirement, and we do that 24 by 7 by 365. We also do one-on-one client management. So what I mean by that is, each one of our customers has a debriefing session once a week with a set engineer and a set sales or technician support person on our side, and the purpose of those calls is to go through everything that happened the week before within our security service for the customer, and also talk about things that they’re seeing being an issue, where we can help be more responsive or broaden our offering to them, etcetera.

What that ends up doing is, it really allows our customers to feel like we are clearly an extension of their business, because they are one-on-one with those people each week, and we don’t change those people out. So when one of our engineers is assigned to that account, that is their responsibility.

James West:     Did any of your clients, or have any of the clients in the last year, experienced any of the major outages that other large corporations suffered as a result of the large-scale virus attacks that we’ve seen in the news lately?

Chris Blisard:     They have not. Our customers were not impacted by Wanna Cry or Petya or some of these other cyber attacks that were out there. We obviously are very proactive with our customers; we cross, we do the monitoring as well as the managing, we are on top of a lot of what potentially could be an outage for them.

But, luckily enough, none of our customers were hurt by those outbreaks.

James West:     Sure. Okay, is it safe to say that the fact that you were able to protect your customers at the enterprise level – is that pretty much representative of the opportunity for Virtual Armour going forward right now?

Chris Blisard:     It absolutely is. 75 percent of our business, or our company right now, are engineers, ranging from professional services to managed services engineers. So when you look at that from an overall company portfolio, we are clearly set up to support very high end, very complicated networks.

For us, that’s the main focus of our business, and that’s where we focus on supporting our custome

CIBT Education Group Inc. (TSE:MBA) (OTCMKTS:MBAIF) is one of the largest private colleges in Canada, as well as a student housing company. With the company witnessing the doubling of international student enrollment, President and CEO Toby Chu speaks to James about building on the momentum in the Metro Vancouver area, as well as doubling their stock price within a …

Original article: PODCAST: CIBT Education Group President and CEO Toby Chu on Building Revenue in the International Student Housing Market

©2018 Midas Letter. All Rights Reserved.

Brixton Metals Corporation (TSX-V:BBB) (OTCMKTS:BXTMF) (FRA:8BX1) is a mining company focused on high-grade silver and gold. We spoke to CEO Gary Thompson who gave us an update on three major projects: the Thorn Gold-Silver project in British Columbia, the Hog Heaven Silver-Gold project in Montana, and the Langis-Hudson Bay Silver-Cobalt project in Ontario, the latter of which boasts mineral …

Original article: PODCAST: Brixton Metals CEO Gary Thompson on their Mining Projects in B.C. and Montana, and Investing in more Cobalt

©2018 Midas Letter. All Rights Reserved.

Emerald Health Therapeutics Inc. (TSX.V:EMH) (OTCQX:EMHTF) (FRA:TBD) is a licensed producer of medical cannabis and distributes through an e-commerce platform. CEO Bin Huang talks about the company’s transition into a large-scale licensed producer, as well as adapting to advertizing regulations once recreational marijuana is legalized in Canada in 2018.

TRANSCRIPT:

James West:     Bin, thank you for joining me today.

Bin Huang:     Thank you, James, for the invitation. Pleasure to be speaking here.

James West:     Bin, let’s start with an overview: what exactly is the value proposition to the investors in Emerald Health?

Bin Huang:     Yeah. Emerald Health is a licensed producer in Canada. We actually have for medical cannabis, we actually have a full set of licenses. We cultivate cannabis, we manufacture cannabis oils, and we sell dried cannabis and cannabis oils for medical purposes using our e-commerce platform. So the value proposition is that we have a medical focus. Our team has very extensive experience in medical research, and also in operations – execution of business strategy.

As a licensed producer, we have a very excellent track record, but right now this year, we are on the cusp of transformation into a very large-scale licensed producer, just in time, ready for the legal market next year in Canada. And I think relative to other major licensed producers that have a million square foot capacity, we are nowhere near the valuation, so I think that’s a very compelling situation for us to be in, facing the transformational growth this year.

James West:     Sure. So you have 500,000 square feet under cultivation now?

Bin Huang:     The current facility we have now is a pilot facility in Victoria, British Columbia, and we do our cultivation there, but it’s a pilot facility. The growth, the expansion, is what we are focusing on, and we actually have two major projects. One is the joint venture with Village Farms, and that has an existing 1.1 million square foot of state-of-the-art greenhouse already in place and operational; we just need to do the retrofitting and get the Health Canada license for it to be used for cannabis.

James West:     And how long do you anticipate that will take you?

Bin Huang:     Well, we want to be ready for legalization. So mid-next year, we want to be growing and we want to start harvesting. So that’s the very aggressive timeline we are targeting.

James West:     Right.

Bin Huang:     And the other major piece of growth plan, expansion plan, is our Metro Vancouver property. We leased 32 acres of land, and that is big enough to build another 1 million square foot of growth space, but we are taking a modular approach. So the first two phases will just be 50,000 square foot each, and that will be 100,000 total in cultivation space, and that’s for high-quality indoor growing and also for extraction, for processing, for the infrastructure there.

James West:     Wow. Okay, so you’re diversified across greenhouses and indoor, you’re diversified across British Columbia, I guess. How many patients – do you have patients that you sell to now, and if so, how many, and where are they based?

Bin Huang:     So we do sell to patients. We started selling dried, I think two years ago, a

Novo Resources Corp (CVE:NVO)(OTCMKTS:NSRPF)(FRA:1NO), a featured Midas Letter pick from 2011, has been a long time coming, but Chairman and President Dr. Quinton  reminds subscribers that this extraordinary Witwatersrand look-alike is the result of the theory that first attracted Dr. Hennigh to the project in the first place. He explains the remarkable relationship between the precipitation of gold due …

Original article: Novo Resources Corp President Quinton Hennigh on Witwatersrand 2.0

©2018 Midas Letter. All Rights Reserved.

MGX Minerals Inc. (CNSX:XMG) (OTCMKTS:MGXMF) (FRA:1MG) Chairman Marc Bruner talks to James about producing petro-lithium, and cutting well costs by not fracking.

TRANSCRIPT:

James West:     Marc, thanks for joining us today.

Marc Bruner:     Glad to be here.

James West:     Marc, last time we spoke was back in May, and since then, MGX Minerals announced a national instrument 51-101 estimated …

Original article: PODCAST: MGX Minerals Chairman Marc Bruner on Producing Two Revenue Streams: Lithium and Oil

©2018 Midas Letter. All Rights Reserved.

InMed Pharmaceuticals Inc. (CNSX:IN) (OTCMKTS:IMLFF) (FRA:MWG2) performs research on extracted and purified cannabinoids to treat severe disease. President and CEO Eric Adams talks to James about the Canadian cannabinoid market, patenting, and their research on oils to treat a rare skin disorder often first seen on children.

TRANSCRIPT:

James West:     Eric, thanks for joining me today.

Eric Adams:     Thanks for having me.

James West:     Eric, why don’t you give me an overview: what is it that InMed does?

Eric Adams:     Well, InMed is a pharmaceutical company that works with a class of compounds called cannabinoids. These are a type of compound that’s typically found in nature in the cannabis plant. There are over 90 different cannabinoids, different drugs, in the cannabis plant, and what we do is, we work with purified versions of those drugs and we apply …

Original article: InMed President and CEO Eric Adams on the Future of Treating Disease with Cannabinoids

©2017 Midas Letter. All Rights Reserved.

Cronos Group Inc. (CVE:MJN) (OTCMKTS:PRMCF) (FRA:7CI) is an ACMPR company that grows their cannabis in Israel and distributed to the Canadian and international market. CEO Mike Gorenstein talks about their $40 million debt deal acquired in August and selling in the medical industry.

TRANSCRIPT:

James West:     Hey Mike, welcome back to the show.

Mike Gorenstein:     Thanks. Glad to be back.

James West:     Mike, I want to focus today on the unconventional things that Cronos Group is doing as an ACMPR multi-licensee to differentiate itself from the run-of-the-mill ACMPR company, which it’s getting harder to distinguish between thanks to all the new licenses. Let’s start with what’s going on in Israel for you guys.

Mike Gorenstein:     Sure. Thanks. Yeah, so that’s one of the biggest things Cronos has done to date from my perspective. I think it’s extremely significant, …

Original article: Cronos Group CEO Mike Gorenstein on Growing Cannabis in Israel and their $40 Million Debt Deal

©2017 Midas Letter. All Rights Reserved.

Teranga Gold Corporation (TSE:TGZ) (OTCMKTS:TGCDF) (FRA:0TGA) currently averages gold production of 200,000 ounces at the Sabodola mine in Senegal. President and CEO Richard Young talks about the new Banfora mine (expected to be ready by 2019) in Burkina Faso, which the company predicts will bring production to a total of 500,000 ounces a year.

TRANSCRIPT:

James West:     Richard, thank you for joining us today.

Richard Young:     James, it’s a pleasure to be here.

James West:     Richard, let’s start with an overview of exactly what Teranga Gold is up to in Senegal.

Richard Young:     Well, Teranga operates the only commercial gold mine in the country. Came into production in 2009. We just released an updated technical report for the project in July, and it increased reserves to 2.7 million ounces. We have a remaining mine life of 14 years, all-in sustaining costs sub-$900 an ounce, which we believe is quite competitive.

Over the next five years, we will average 200,000 ounces per year, and 176 life of mine – and there’s still a lot of exploration potential both on the mine license and our regional land package. So we expect to continue to add reserves to Sabodala, and would target to be able to maintain 200,000 ounces per year beyond the next five years.

James West:     Okay, so one of the first questions that pops into anybody’s mine when they hear about anywhere in Africa is, what’s the political climate like there in terms of stability and insurgent activity, if any?

Richard Young:     Well, Senegal is possibly the most democratic country in Africa. Since it gained independence from France in 1960, there have been peaceful elections. In 2012, on the tail end of the Arab Spring, there was an election which the incumbent president was running for a third term, and he lost, and he had peacefully handed over control of the government to the incoming president, and the rule of law is followed.

Senegal and all of French West Africa is very closely aligned with France, Europe and North America, and it’s very easy to do business. In terms of insurgencies, whether it’s Senegal or anywhere else in West Africa, it’s quite limited to tourist locations, and there have been a few instances in West Africa – again, it’s all focused on tourist locations similar to what we’ve seen in London and Paris. But otherwise, Senegal, as well as elsewhere in French West Africa, is pretty safe and stable.

James West:     Sure. Okay, well, that’s relieving! Tell us a bit abou